Gene therapy promises to be a singular advance in treatment of both acquired and genetic diseases at the most fundamental levels of pathology. Specifically, the development of gene transfer methods into hepatocytes is very attractive given the central role that the liver plays in many inborn errors of metabolism and acquired disorders. One of the problem areas in gen therapy is the sustained expression of transgenes at high levels in the liver. This project will use an innovative approach to develop regulatory elements that will enable high and stable levels of foreign gene expression in the liver. These regulatory elements can include transcriptional elements such as promoters, enhancers and locus control regions, but also other elements like introns, 5' and 3' untranslated regions and polyadenylation (polyA) addition signals. These elements should be directly applicable to generate both improved viral and non-viral gene therapy vectors. In phase I studies, the development of a system is proposed that will allow for the efficient selection of such regulatory elements. This system will also enable selection for sequences that direct persistence of foreign DNA by chromosomal integration or extrachromosomal maintenance. During the phase II studies, the in vivo selection system will be applied to the development of promoters that enable high and stable levels of foreign gene expression in the liver. Such promoters will be used in phase III for the internal development of non-viral vectors for gene therapy applications such as for hemophilia A (factor VIII) within Mirus and licensed to other gene therapy, biotechnology and pharmaceutical companies for use within their non-viral and viral vectors. The development of a clinically viable gene expression system should have tremendous commercial value, given the critical role that it would play in gene therapy (estimated to be a multibillion market by the year 2000).

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44DK055932-03
Application #
6350735
Study Section
Special Emphasis Panel (ZRG1-SSS-2 (01))
Program Officer
Mckeon, Catherine T
Project Start
1999-08-01
Project End
2002-01-31
Budget Start
2001-02-15
Budget End
2002-01-31
Support Year
3
Fiscal Year
2001
Total Cost
$389,150
Indirect Cost
Name
Mirus Bio Corporation
Department
Type
DUNS #
937904944
City
Madison
State
WI
Country
United States
Zip Code
53711
Wooddell, Christine I; Reppen, Thomas; Wolff, Jon A et al. (2008) Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery. J Gene Med 10:551-63
Wooddell, Christine I; Van Hout, Cristopher V; Reppen, Thomas et al. (2005) Long-term RNA interference from optimized siRNA expression constructs in adult mice. Biochem Biophys Res Commun 334:117-27